Effect of doxorubicin/pluronic SP1049C on tumorigenicity, aggressiveness, DNA methylation and stem cell markers in murine leukemia.

Abstract

PURPOSE:

Pluronic block copolymers are potent sensitizers of multidrug resistant cancers. SP1049C, a Pluronic-based micellar formulation of doxorubicin (Dox) has completed Phase II clinical trial and demonstrated safety and efficacy in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. This study elucidates the ability of SP1049C to deplete cancer stem cells (CSC) and decrease tumorigenicity of cancer cells in vivo.

EXPERIMENTAL DESIGN:

P388 murine leukemia ascitic tumor was grown in BDF1 mice. The animals were treated with: (a) saline, (b) Pluronics alone, (c) Dox or (d) SP1049C. The ascitic cancer cells were isolated at different passages and examined for 1) in vitro colony formation potential, 2) in vivo tumorigenicity and aggressiveness, 3) development of drug resistance and Wnt signaling activation 4) global DNA methylation profiles, and 5) expression of CSC markers.

RESULTS:

SP1049C treatment reduced tumor aggressiveness, in vivo tumor formation frequency and in vitro clonogenic potential of the ascitic cells compared to drug, saline and polymer controls. SP1049C also prevented overexpression of BCRP and activation of Wnt-β-catenin signaling observed with Dox alone. Moreover, SP1049C significantly altered the DNA methylation profiles of the cells. Finally, SP1049C decreased CD133(+) P388 cells populations, which displayed CSC-like properties and were more tumorigenic compared to CD133(-) cells.

CONCLUSIONS:

SP1049C therapy effectively suppresses the tumorigenicity and aggressiveness of P388 cells in a mouse model. This may be due to enhanced activity of SP1049C against CSC and/or altered epigenetic regulation restricting appearance of malignant cancer cell phenotype.

• Authors: Daria Y Alakhova, Yi Zhao, Shu Li, Alexander V Kabanov
• Journal: PloS one (PLoS One) Vol. 8 Issue 8 Pg. e72238 ( 2013) ISSN: 1932-6203 [Electronic] United States
• PMID: 23977261 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• AC133 Antigen
• ATP Binding Cassette Transporter, Subfamily G, Member 2
• ATP-Binding Cassette Transporters
• Abcg2 protein, mouse
• Antigens, CD
• Antineoplastic Agents
• CTNNB1 protein, mouse
• Glycoproteins
• PROM1 protein, human
• Peptides
• Prom1 protein, mouse
• SP 1049C
• Wnt Proteins
• beta Catenin
• Poloxamer
• Doxorubicin

Topics

• AC133 Antigen
• ATP Binding Cassette Transporter, Subfamily G, Member 2
• ATP-Binding Cassette Transporters (antagonists & inhibitors, genetics, metabolism)
• Animals
• Antigens, CD (genetics, metabolism)
• Antineoplastic Agents (pharmacology)
• Ascites
• DNA Methylation (drug effects)
• Doxorubicin (analogs & derivatives, pharmacology)
• Drug Resistance, Neoplasm (drug effects)
• Female
• Gene Expression Regulation, Neoplastic
• Glycoproteins (antagonists & inhibitors, genetics, metabolism)
• Humans
• Leukemia P388 (drug therapy, genetics, metabolism, pathology)
• Mice
• Neoplasm Invasiveness (prevention & control)
• Neoplastic Stem Cells (drug effects, metabolism, pathology)
• Peptides (antagonists & inhibitors, genetics, metabolism)
• Poloxamer (analogs & derivatives, pharmacology)
• Tumor Cells, Cultured
• Wnt Proteins (antagonists & inhibitors, genetics, metabolism)
• Wnt Signaling Pathway
• beta Catenin (antagonists & inhibitors, genetics, metabolism)